SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration
2009

SU5416 Causes Early Aging in Blood Vessel Cells from AMD Patients

Sample size: 3 publication Evidence: moderate

Author Information

Author(s): Michelle Thill, Marc J. Berna, Frank Kunst, Henning Wege, Natalya V. Strunnikova, Natalya Gordiyenko, Rebecca Grierson, Richard Gisbert, Karl G. Csaky

Primary Institution: Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Hypothesis

Can SU5416 and other VEGF inhibitors induce premature senescence in endothelial progenitor cells from patients with age-related macular degeneration?

Conclusion

SU5416 and other inhibitors lead to cell death and early aging in endothelial progenitor cells, which may be a target for treating age-related macular degeneration.

Supporting Evidence

  • SU5416 treatment increased apoptosis in endothelial progenitor cells.
  • Long-term treatment with SU5416 reduced cell proliferation and telomerase activity.
  • Cells treated with SU5416 showed signs of premature senescence.

Takeaway

This study found that a drug called SU5416 makes certain blood vessel cells age faster, which could help in treating eye problems in older people.

Methodology

Endothelial progenitor cells were isolated from patients and treated with SU5416 and other inhibitors to assess apoptosis, proliferation, and senescence.

Limitations

The study primarily focused on in vitro conditions and may not fully represent in vivo responses.

Participant Demographics

Patients with neovascular age-related macular degeneration.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication